Quantum BioPharma is trading 5.04% up now at $3.23 after Rodman & Renshaw initiated coverage on August 31, 2026, with a Buy rating and an $8.00 price target based on Lucid-MS potential.
- The report highlights Lucid-MS as a potentially first-in-class treatment candidate for progressive multiple sclerosis.
- The publication was disseminated on behalf of the company and may include paid advertising, limiting confidence in the catalyst’s independent validation.